MRK vs RVTY: fair value comparison
Merck & Co., Inc. and Revvity, Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, RVTY currently sits closer to the top of our discount ranking. RVTY carries the stronger quality grade.
| MRK | RVTY | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $150.33 | $130.22 |
| 12-month range | $82.49–$149.86 | $86.68–$126.59 |
| Sector rank | #95 of 113 Healthcare | #90 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: MRK fair value analysis · RVTY fair value analysis